Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshua Brody

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Blood|December 10, 2014
Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cellsJonathan Reichel, Amy Chadburn, Paul G Rubinstein, et al.
The Journal of Clinical Investigation|June 4, 2013
Depleting tumor-specific Tregs at a single site eradicates disseminated tumorsAurélien Marabelle, Holbrook Kohrt, Idit Sagiv-Barfi, et al.
Journal for Immunotherapy of Cancer|October 10, 2020
Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumorsLillian Siu, Joshua Brody, Shilpa Gupta, et al.
Future Oncology (London, England)|April 7, 2020
ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1Grzegorz S Nowakowski, Jun Zhu, Qingyuan Zhang, et al.
Immunity|April 21, 2016
Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF InhibitionHélène Salmon, Juliana Idoyaga, Adeeb Rahman, et al.
Cancer Cell|January 23, 2026
Armored macrophage-targeted CAR-T cells reset and reprogram the tumor microenvironment and control metastatic cancer growthJaime Mateus-Tique, Ashwitha Lakshmi, Bhavya Singh, et al.
Future Oncology (London, England)|December 10, 2025
Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphomaNathalie A Johnson, Pier Luigi Zinzani, Eva Domingo-Domenech, et al.
Haematologica|March 5, 2026
Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trialPau Abrisqueta, Yasmin H Karimi, Daniel Morillo, et al.
Blood|January 22, 2024
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapyJennifer L Crombie, Tara Graff, Lorenzo Falchi, et al.
The Lancet. Haematology|January 16, 2019
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a studyAnas Younes, Joshua Brody, Cecilia Carpio, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Blood|December 10, 2014
Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cellsJonathan Reichel, Amy Chadburn, Paul G Rubinstein, et al.
The Journal of Clinical Investigation|June 4, 2013
Depleting tumor-specific Tregs at a single site eradicates disseminated tumorsAurélien Marabelle, Holbrook Kohrt, Idit Sagiv-Barfi, et al.
Journal for Immunotherapy of Cancer|October 10, 2020
Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumorsLillian Siu, Joshua Brody, Shilpa Gupta, et al.
Future Oncology (London, England)|April 7, 2020
ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1Grzegorz S Nowakowski, Jun Zhu, Qingyuan Zhang, et al.
Immunity|April 21, 2016
Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF InhibitionHélène Salmon, Juliana Idoyaga, Adeeb Rahman, et al.
Cancer Cell|January 23, 2026
Armored macrophage-targeted CAR-T cells reset and reprogram the tumor microenvironment and control metastatic cancer growthJaime Mateus-Tique, Ashwitha Lakshmi, Bhavya Singh, et al.
Future Oncology (London, England)|December 10, 2025
Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphomaNathalie A Johnson, Pier Luigi Zinzani, Eva Domingo-Domenech, et al.
Haematologica|March 5, 2026
Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trialPau Abrisqueta, Yasmin H Karimi, Daniel Morillo, et al.
Blood|January 22, 2024
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapyJennifer L Crombie, Tara Graff, Lorenzo Falchi, et al.
The Lancet. Haematology|January 16, 2019
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a studyAnas Younes, Joshua Brody, Cecilia Carpio, et al.
Pageof 5